Compare Cognizant Technology Solutions Corp (CTSH) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Eli Lilly And Co — how do they compare? Cognizant Technology Solutions Corp trades at $59.26 (market cap $27.03B), while Eli Lilly And Co trades at $1,178.99 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 38.5× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.2%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Eli Lilly And Co for 93 Days on average.
| CTSH | LLY | |
|---|---|---|
Market Cap | $27.03B | $1.04T |
Volume | 9,883,888 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $86.70 | $1.28K |
52-Week Low | $38.73 | $799.57 |
Typical Hold Time | 57 Days | 93 Days |
Enterprise Value | $28.08B | $1.09T |
Dividend Yield | 2.2% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.43, up 4.14% on the day, with a bullish technical signal from moving averages and support at $56. The company reported revenue of $21.11B in 2025, with a net income margin of 10.26%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights its AI-driven initiatives and recognition as a top employer, reinforcing its competitive positioning in IT services.
CTSH presents a value opportunity with a P/E of 12.88 below sector averages, supported by stable cash flow and a consensus price target of $64.25. Risks include competitive pressures in IT services and potential volatility around the upcoming Q3 earnings report. The stock's current valuation and analyst buy ratings suggest upside potential, though investors should monitor execution on AI integration.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
